-+ 0.00%
-+ 0.00%
-+ 0.00%

Palvella Therapeutics Granted FDA's Fast Track Designation To QTORIN Rapamycin To Treat Angiokeratomas

Benzinga·12/16/2025 12:35:18
Listen to the news

(Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that the FDA has granted Fast Track Designation to QTORIN™ rapamycin for the treatment of angiokeratomas.